Just a few highlights that I copy and pasted here.

Application to the treatment of CNS indications for Lysosomal Storage Diseases (“LSD”).....This program is continuing with additional work anticipated to be complete by Q2 2017. 

Oncology Program – Delivery of Lead Candidate Trastuzumab (Herceptin®) across the BBB – The MTf-TZM Program.......plans are underway to perform a Phase Zero Phase study for measuring BBB transport of MTfp-TZM in humans. 

Internal Development Programs and Commercial Business Strategies.....Given the lack of human clinical data, most pharmaceutical companies require internal evaluation and validation studies. Coupled with the global failures so far of several blood-brain barrier delivery systems the companies are cautious, slowing the adoption time and making clear to us the necessity for biOasis-directed human clinical trials. 

The Company is pushing forward on two internal programs, one with Dr. Scarpa on MPSII and the Trastuzamab program with the Phase Zero team in Australia. Although both of these programs have caught the interest of Pharmas, we as a company are focused, pending adequate financial resources, to moving forward with both programs in humans. Extensive protocols have been designed and approved and both Dr. Scarpa and the Phase Zero team in Australia are ready to begin these studies.

FUTURE OUTLOOK The Company will continue to need to raise funds for its future operations and for its preclinical programs potentially leading to the filing of one or a number of Investigational New Drugs (INDs).

Within the Transcend program, management intends to advance pre-clinical development of the MTF-TZM Herceptin® conjugate program, to advance its Transcendpep family program and to fund further pre-clinical work on its LSD program and other preclinical programs as initiated by the Company. With sufficient funds, the Company will expand the scope of work on these projects with the intention of creating greater value for its intellectual property and on building stronger licensing partnerships. To assist in commercialization of biOasis’s technology, biOasis engaged Shadow Lake Group (formerly named Willow Tree Capital Corp.) to perform certain business development activities that will potentially lead to commercial license agreements.